The first successful removal of a parathyroid adenoma was reported to the Viennese Medical Society by Mandl in 1925. During the next 50 years primary hyperparathyroidism was considered to be a very uncommon condition. In 1959, McGeown and Morrison' reported 53 cases from Northern Ireland who had been operated on successfully for primary hyperparathyroidism, and had the foresight to note that 'it is not a rare disease'. More recent studies have confirmed that primary hyperparathyroidism due to a benign adenoma is a relatively common entity, particularly when actively sought2. In the past 10 years, its incidence and clinical presentation have changed dramatically2'3.
In contrast, parathyroid carcinoma remains an infrequent cause of primary hyperparathyroidism: since 1948 about 120 cases have been reported in the literature4 5. Opinions as to its exact incidence have differed from 0.5%6 -8 to around 5% 9.10 of cases of primary hyperparathyroidism. The morphological criteria for diagnosis, the prognosis and the optimal management ofthe disease remain controversial, and individual experience is limited. The histological characteristics that are useful in determining malignancy in other organs seem less applicable to endocrine tumoursespecially tumours ofthe parathyroid glandsand differing diagnostic criteria, coupled with limited experience, have almost certainly contributed to the differing incidence cited by various authors. Despite the considerable Northern Ireland experience in parathyroid disease""I, a biopsy review of parathyroid histology in cases of primary hyperparathyroidism in Northern Ireland from 1930 to 1985 revealed 195 cases ofparathyroid adenoma, 94 of hyperplasia and only one (see below) parathyroid carcinomaan incidence ofcarcinoma ofaround one in 300 cases ofhyperparathyroidism (0.3%). Since the increased diagnosis of primary hyperparathyroidism during the last two decades has not resulted in any increase in reports of parathyroid carcinoma, it seems probable that the true incidence of carcinoma is less than one in 100 cases of hyperparathyroidism6'7"2.
Aetiology
There are a few reports of carcinoma in association with familial hyperparathyroidism'3. There have also been reports, despite earlier views to the con-trary9, of carcinoma occurring within an adenoma or in a hyperplastic gland"' 16 . Parathyroid carcinoma has been described in several patients receiving dialysis, and attention has recently been drawn to the possibility of radiation-induced malignant change in hyperplastic tissue'7. Several cases have been reported of apparently benign 'parathyroid adenomas' associated with distant metastases'5"9, but the original diagnosis of the benign adenoma must be in doubt.
Symptoms and diagnosis
The diagnostic differences between benign and malignant functioning parathyroid tumours have been clarified by the modern clinical profile ofbenign hyperparathyroidism3'9 , 19-22 Symptoms ofhyperfunctioning parathyroid carcinoma are mainly those of hypercalcaemia, as the serum calcium levels are usually much higher than those seen in patients with benign parathyroid disease, and the symptoms are more severe3 2. Schantz and Castleman9, in a review of 70 patients with parathyroid carcinoma, found an average initial serum calcium of3.8 mmol/l, 62% of the patients showing levels above 3.5 mmol/l. Corresponding figures reported by Holmes et al.20 were 3.98 mmol/l and 75%, and those of Shane and Bilezikian'2 were 3.88 and 70% respectively. These figures should be compared with the milder elevations of serum calcium usually seen in benign disease. There are much higher levels of circulating immunoreactive parathyroid hormone (two to five-fold increases) in carcinoma12 '22. In contrast to the benign parathyroid adenoma, which has a 3:1 preponderance in women, parathyroid carcinoma affects men and women with equal frequency'2 20. Patients with carcinoma are often younger than those with benign parathyroid disease the mean age in two independent reviews was 44-48 years'2"9'20. Of 41 patients reviewed by Shane and Bilezikian'2, all but one were clearly symptomatic.
The most common symptoms were polyuria and polydipsia occurring in 35% of patients, followed by general weakness, fatigue, anorexia, nausea, vomiting and weight loss. The kidneys and the bones, classical targets for parathyroid hormone, were affected more frequently and more severely than in benign primary hyperparathyroidism. Renal disease was present in 37 of 47 patients; 72% of these had nephrolithiasis, 21% nephrocalcinosis and 55% impairment of renal function. Holmes et al.20, in an earlier review of 46 patients, found renal disease in 15, many with symptoms of renal colic. Skeletal disease is found in between 55% and 73% of cases, including osteoporosis, subperiosteal bone resorption and osteitis fibrosa cystica, with symptoms of bone pain and pathological fracture. Concomitant renal and skeletal disease occurred frequently, which is a rarity in benign hyperparathyroidism. Acute, often recurrent, pancreatitis has been reported in several patients, and anaemia is more common than in patients with benign parathyroid disease'2"3"9'20 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 Another striking difference from benign parathyroid disease is the presence of a palpable neck mass. In benign parathyroid disease, a neck mass can be felt in less than 10% of patients8. According to reviews by Schantz, Shane and Holmes, a neck tumour can be felt in 30-0W% of patients with parathyroid carcinoma9' .220* Unilateral paralysis of the recurrent laryngeal nerve in connection with hyperparathyroidism is another sign suggestive of canceras is late recurrence after surgery20, particularly if a single large gland was removed, and the operation resulted in interim relief for a significant period of time. A propensity for inferior gland involvement has been described8.
Unfortunately, despite an appropriate index of suspicion, some tumours will continue to present diagnostic difficulties. We recently encountered such difficulty in a patient with a 13-year history ofpersistent hyperparathyroidism, in whom the diagnosis of parathyroid carcinoma ultimately was confirmed at necropsy ( Figure 1 ). Case report TS first presented to the ENT department at the Royal Victoria Hospital in 1953 aged 53, with a six-week history of vertigo. She was otherwise asymptomatic, with no palpable neck masses. Hypercalcaemia was diagnosed incidentally on biochemical screening, the serum calcium being as high as 5.2 mmol/l (normal range 2.2-2.5), serum phosphate 2.0mmol/l and serum parathyroid hormone (PTH) 3.2 pg/l (normal <0.53). Intravenous calcitonin therapy reduced the serum calcium to 3.3 mmol/l, and at surgery three days later a 3 x 2 x 1 cm parathyroid adenoma was removed from the left superior region of the neck. This was initially reported as a chief cell parathyroid adenoma. All cither usual sites in the neck were explored, and no other parathyroid tissue was identified. Postoperatively the calcium fell to a minimum of 2.65 mmol/l by discharge, but had risen again to 2.75 at one month, and was 3.2 mmol/l three months postoperatively. Hypercalcaemia persisted for the next 12 years.
Six further exploratory operations (5 cervical and one mediastinal) were performed between 1973 and 1985 after various attempts to localize abnormal parathyroid tissue including thallium scintigraphy, CT scanning neck and internal mammary venous sampling and angiography. Surgery included exploration of the usual ectopic sites, a left total thyroid lobectomy and removal ofa normal thymus gland. Two further parathyroid glands were identified, the first at the fifth operation in 1980, consistent with the right inferior gland (small chiefcell adenoma), and asmall hyperplastic fragment ofparathyroid tissue at the left inferiorsite at the sixth operation in 1983. No changes in serum calcium followed any of these procedures, and serum parathormone remained measureable throughout. Chest radiology was normal. A variety of pharmacological measures failed to reduce calcium levels below 3.0 mmol/l. She finally died of advanced Von Recklinghausen's disease, following fracture of both femoral necks and collapse of the vertebral column with a complicating deep venous thrombosis and pulmonary embolus.
Histopathology
Opinions differ about the diagnosis of parathyroid carcinoma by histological examination in the absence of infiltration or metastasis. Some consider this is not possible6'20, but Castleman and associates have always maintained that with attention to detail the correct interpretation may be made. The importance ofmitoses, a trabecular architecture, adherence to surrounding tissues and to some extent capsular invasion and the extension-offibrous trabeculae from the capsule into the tumour was emphasized in the diagnosis of carcinoma2'3. In the revised AFIP Fascicle in 197824, in addition to these features, the grey/ tan colour, the hard consistency andthe lobulated cut surface of many carcinomas were stressed. The presence of mitoses within parenchymal cells was considered to be the single most valuable criterion18'24, while cellular atypia and variation were not helpful.
Subsequent authors have largely adopted these criteria, although reservation has been expressed regarding the significance of vascular and capsular invasion18'25'26, and some feel that mitotic activity alone is an unreliable indicator of aggressive potential in parathyroid tissue. Snover and Foucar27 found increased mitotic figures in the parenchymal cells of 12 of 17 adenomas, and 8 of 10 hyperplasias. Even when mitotic figures are absent, 'benign adenomas' may metastasize18 27, and Schantz and Castleman9 described 10% of cases of parathyroid carcinoma with metastases which lacked mitoses. It is important to consider the overall picture, rather than a single criterion26.
In the case reported here, prompted by the autopsy findings, a reappraisal of the original 1973 tissue blocks was made which indicated that the lesion was parathyroid carcinoma from the onset. Histology revealed a cellular-tumour with a thick fibrous capsule and prominent fibrous septae ( Figure   2 ). Mitotic figures were absent, but the tissue was very vascular, and there -were some areas showing capsular invasion and infiltration of adjacent thyroid tissue with perineural and lymphatic infiltration. Tumour infiltration of a small vessel, with associated thrombosis, was seen (Figure 3) . At autopsy careful examination of the neck and mediastinum had revealed no recognizable parathyroid glands in usual or ectopic sites. Dissection of scar tissue revealed a firm, greyish-yellow nodule, 1.5 cm in maximum dimension, adherent to the right posterolateral aspect of the trachea, and multiple smaller nodules embedded in scar tissue on both sides of the upper trachea. Histology of all these nodules showed dense scar tissue containing irregular masses of cells, separated by thick hyalinized fibrous septae (Figure 4) . In several of the nodules, there was evidence of perineural and lymphatic infiltration ( Figure 5 ). Vascular invasion was not seen. No organized lymphoid tissue was seen in relation to any of the tumour nodules to suggest that these were lymph node metastases. The subpleural parenchyma of the posterior aspect of the lower lobe of the left lung contained multiple discrete greyish/brown nodules, ranging in diameter from 0.3 to 1.0 cm. Histologically, these nodules consisted of tumour similar in pattern and cellular morphology to that in the neck. Immunoperoxidase studies showed positive staining of both neck and lung tumour for neurone-specific enolase (a histological marker of neuroendocrine differentiation). Staining for the presence ofparathormone using an indirect immunofluorescent technique was positive. The kidneys showed nephrocalcinosis with, in addition, the incidental diagnosis of a renal tubular adenoma showing oncocytic differentiation. Osteitis fibrosa cystica was present in several bones including the ribs, vertebrae and clavicle.
Treatment
Even if the primary operation is considered successful, 30-65% of the patients will eventually develop (H&E x 150.) recurrent disease9 20. Local tumour recurrence is most common, but metastases also appear especially in cervical nodes (30-32%), lung (10-40%), liver (10%) and bone (7%)7.9,12.20. Recurrence manifests itself by a rising serum calcium. Since patients dying from parathyroid carcinoma usually succumb from the effects of hypercalcaemia, several authors have emphasized that resection of recurrent tumour or functioning metastases should be considered both in terms of palliation and in facilitating adjunctive medical therapy8'20. As parathyroid carcinoma is an indolent malignancy with marked tenacity22, a significant palliation may be achieved for a considerable period of time by this approach, but only very rarely is a patient with recurrent disease cured. When surgical efforts at curative or palliative resection are unsuccessful or no longer possible, other methods of treatment should be tried, but in general these have met with little or only transient success.
Theoretically, calcitonin should be the drug of choice because ofits ability to inhibit parathormonestimulated bone resorption and its lack of toxic effects. However, an encouraging initial effect of calcitonin is often difficult to sustain for more extended periods of time'2. The administration of calcitonin in combination with prednisone may be more promising28, and a combination with diphosphonate has been recommended for severe cancer-associated hypercalcaemia29. Mithramycin, a cytotoxic antibiotic, has been successful in a few patients with parathyroid carcinoma'5, but the drug has to be administered intravenously and toxicity (liver, kidney and bone marrow) which is dose-related is quite common, necessitating titration to the lowest possible effective dose. Oral phosphate appears to be universally ineffective in the setting of such severe hypercalcaemia. Diphosphonates have been successful when administered intravenously, reducing the serum calcium in several patients, but are unsuccessful orally. Treatment with oestrogen and testosterone, tried in a few patients, resulted in only minimal and transient success'9'30. A combination of tumoricidal agents resulted in the complete disappearance of pulmonary metastases and regression of hypercalcaemia in one patient for over five months"6. Radiotherapy has been given to a limited number of patients, but without significant effect2 4'20. Perhaps the answer will lie with the parathyroid hormone antagonist3' -a concept which is no longer hypothetical.
Survival and prognosis
As can be seen from our own case, the disease is compatible with prolonged survival, even when metastatic disease is present, making it amenable to repeated resection of local recurrences or distant metastases for palliation8, but seldom cure'2. Three patients have been reported alive with known metastases 15 or more years after initial surgery, including one of 33 years' duration'2. Death in patients with parathyroid carcinoma is usually due to the cardiac and renal sequelae of uncontrolled hypercalcaemia rather than to local invasion or distant metastases. The five-year survival appears to be less than 50% and the 10-year survival less than 35% although figures vary, and recently a review of8 cases noted only one patient who suffered a local recurrence, the only death being due to primary lung cancer32. Given the indistinct morphological and histological features of parathyroid carcinoma, it would seem likely that cases will continue to be suggested postoperatively by the pathologist and ultimately confirmed by recurrence of the disease33.
Some have remarked pessimistically on how little progress has been made in diagnosis or therapy since the first series of parathyroid carcinoma was published in 194832. Clarification of the problem will only be achieved by further standardization of the diagnostic criteria, continual review of all available histology and appropriation of the guidelines for optimal treatment which are now beginning to emerge. Firstly, the treatment of parathyroid carcinoma remains surgical8. Extensive yet meticulous en bloc resection at initial surgery offers the best chance for cure for patients with parathyroid carci-22.3 noma .32. Most investigators now advocate excision of the lesion with ipsilateral thyroidectomy including the isthmus, if the tumour is confined within the capsule and there is no apparent lymph node involve-ment7"'0, in contrast to the original suggestion of more radical neck surgery involving ipsilateral lymph node dissection20. Secondly, the surgeon must be constantly aware of the possibility of parathyroid malignancy8 and extreme care must also be taken to avoid capsular violation or tumour spillage22. Carcinoma of the parathyroid, if diagnosed early and treated adequately, might be expected to lead to more gratifying long-term results7'8"l0 ' 25 Non-functioning parathyroid carcinoma The existence of this entity is controversial. The lack of clear-cut diagnostic histologic criteria and the histologic resemblance to other malignant tumours such as follicular thyroid carcinoma and metastatic hypernephroma, and the rarity with which such tumours will occur, make its existence difficult to prove. Holmes et al.20 accepted 4 cases for the diagnosis and several others have appeared since. The diagnosis of non-functioning parathyroid carcinoma has generally been based on lack of evidence of hyperparathyroidism, such as normal serum calcium, phosphorus and parathormone concentrations, despite the presence of carcinoma of parathyroid origin.
In other carcinomas, such as those of the thyroid, breast and prostate, analysis of the DNA profile of tumour cells by the stage cell technique has successfully differentiated rapidly growing life-threatening malignancies from less aggressive lesions with similar morphology. Perhaps such an analysis would complement the pathological criteria in parathyroid carcinoma and help to clarify the prognosis of these tumours, which appear similar histologically but differ markedly in virulence32. The recent identification of messenger RNA coding for pre-pro-PTH (PTH mRNA) in an apparently non-functioning parathyroid carcinoma, suggesting that parathormone synthesis is not always absent in parathyroid carcinomas which are not accompanied by hyperparathyroidism, might be useful in establishing the diagnosis of an apparently non-functioning parathyroid carcinoma". An international registry of patients would help to facilitate uniform collection and accurate interpretation of data on these rare tumours32.
